Table 4.
Fabry specific laboratory parameters before the initiation of enzyme replacement therapy
| ID | Gender | Age |
GLA pmol* spot /20 hr |
U‐Gb3 µmol/ mol Crea |
LysoGb3 ng/L |
|---|---|---|---|---|---|
| 1 | M | 15 | 10 | 52 | 110 |
| 2 | M | 33 | 10 | 288 | 105 |
| 3 | M | 35 | 25 | 69 | 88 |
| 4 | M | 38 | 0 | 83 | N.A. |
| 5 | F | 25 | 135 | 17 | 5 |
| 6 | F | 32 | N.A. | 75 | 6 |
| 7 | F | 47 | 115 | 5 | 4 |
| 8 | F | 49 | 153 | 12 | N.A. |
| 9 | F | 53 | 62 | 116 | 17 |
| 10 | F | 60 | N.A. | 20 | 6 |
| 11 | F | 62 | 81 | 19 | 5 |
| 12 | F | 61 | N.A. | N.A. | N.A. |
| 13 | F | 68 | 82 | 41 | 13 |
| 14 | F | 82 | N.A. | N.A. | N.A. |
GLA, alfa galactosidase A (the GenBank reference sequence NM_000169.2); the reference range was 160–2000 pmol*spot /20 hr. U‐Gb3, globotriaosylceramide in urine; the reference value was 10 µmol/mol creatinine or less. LysoGb3, globotriaosylshingosine in plasma; the reference range was 1.8 ng/ml or less.
Abbreviations: F, female; M, male; N.A., not available.